CA2443995C - Endothelial cell expression patterns - Google Patents

Endothelial cell expression patterns Download PDF

Info

Publication number
CA2443995C
CA2443995C CA2443995A CA2443995A CA2443995C CA 2443995 C CA2443995 C CA 2443995C CA 2443995 A CA2443995 A CA 2443995A CA 2443995 A CA2443995 A CA 2443995A CA 2443995 C CA2443995 C CA 2443995C
Authority
CA
Canada
Prior art keywords
leu
ala
pro
ser
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2443995A
Other languages
English (en)
French (fr)
Other versions
CA2443995A1 (en
Inventor
Eleanor Carson-Walter
Brad St. Croix
Kenneth W. Kinzler
Bert Vogelstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of CA2443995A1 publication Critical patent/CA2443995A1/en
Application granted granted Critical
Publication of CA2443995C publication Critical patent/CA2443995C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4703Regulators; Modulating activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7014(Neo)vascularisation - Angiogenesis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7023(Hyper)proliferation
    • G01N2800/7028Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
CA2443995A 2001-04-11 2002-04-10 Endothelial cell expression patterns Expired - Lifetime CA2443995C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28285001P 2001-04-11 2001-04-11
US60/282,850 2001-04-11
US35426202P 2002-02-06 2002-02-06
US60/354,262 2002-02-06
PCT/US2002/008253 WO2002083874A2 (en) 2001-04-11 2002-04-10 Endothelial cell expression patterns

Publications (2)

Publication Number Publication Date
CA2443995A1 CA2443995A1 (en) 2002-10-24
CA2443995C true CA2443995C (en) 2014-06-03

Family

ID=26961707

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2443995A Expired - Lifetime CA2443995C (en) 2001-04-11 2002-04-10 Endothelial cell expression patterns

Country Status (6)

Country Link
US (1) US7393932B2 (cg-RX-API-DMAC7.html)
EP (1) EP1572867B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004533825A (cg-RX-API-DMAC7.html)
AU (1) AU2002258543B2 (cg-RX-API-DMAC7.html)
CA (1) CA2443995C (cg-RX-API-DMAC7.html)
WO (1) WO2002083874A2 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090233270A9 (en) * 2000-08-02 2009-09-17 St Croix Brad Secreted and cytoplasmic tumor endothelial markers
ATE360071T1 (de) * 2000-12-05 2007-05-15 Wisconsin Alumni Res Found Rezeptor für ein toxin aus bacillus anthracis
CN1832965B (zh) * 2003-03-04 2011-03-02 麒麟麦酒株式会社 内皮细胞特异性抗体及其用途
EP1690932A4 (en) * 2003-10-20 2008-03-05 Teijin Pharma Ltd ASSOCIATED WITH BONE AND / OR GAP DISEASES GEN
WO2006029045A2 (en) * 2004-09-03 2006-03-16 Kirin Brewery Co., Ltd. Endothelial cell specific antibodies and uses thereof
WO2006091326A1 (en) * 2005-01-28 2006-08-31 Attogen Inc. Anti-prl-3 antibodies and methods of use thereof
AU2007317753B2 (en) 2006-11-09 2013-11-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Differential gene expression in physiological and pathological angiogenesis
WO2008101118A2 (en) 2007-02-14 2008-08-21 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A gene expression signature identifying pro-angiogenic genes in ovarian tumor endothelial cell isolates
CA2731296A1 (en) * 2008-07-18 2010-01-21 Centre National De La Recherche Scientifique New mutated netrin 4 proteins, fragments thereof and their uses as drugs
US9290556B2 (en) 2008-09-29 2016-03-22 The Trustees Of The University Of Pennsylvania Tumor vascular marker-targeted vaccines
WO2010071938A1 (en) * 2008-12-24 2010-07-01 Commonwealth Scientific And Industrial Research Organisation Novel collagen constructs
CN106074591B (zh) 2010-03-24 2020-01-14 菲奥医药公司 眼部症候中的rna干扰
US9340786B2 (en) 2010-03-24 2016-05-17 Rxi Pharmaceuticals Corporation RNA interference in dermal and fibrotic indications
JP2014524902A (ja) 2011-06-14 2014-09-25 アメリカ合衆国 Tem8抗体、そのコンジュゲートおよびそれらの使用
KR101358810B1 (ko) * 2011-12-30 2014-02-11 한국원자력의학원 방사선 피폭 진단용 마커 igfbp-5, 그 마커의 발현수준을 측정하는 방사선 피폭 진단용 조성물, 그 조성물을 포함하는 방사선 피폭 진단용 키트, 및 그 마커를 이용한 방사선 피폭을 진단하는 방법
CN105813654B (zh) 2013-10-11 2019-05-31 美国政府(由卫生和人类服务部的部长所代表) Tem8抗体及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5695937A (en) 1995-09-12 1997-12-09 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
AU2001283062A1 (en) * 2000-08-02 2002-02-13 The Johns Hopkins University Endothelial cell expression patterns

Also Published As

Publication number Publication date
US20040213793A1 (en) 2004-10-28
EP1572867A4 (en) 2008-03-05
AU2002258543B2 (en) 2008-05-22
EP1572867A2 (en) 2005-09-14
EP1572867B1 (en) 2014-07-23
US7393932B2 (en) 2008-07-01
JP2004533825A (ja) 2004-11-11
CA2443995A1 (en) 2002-10-24
WO2002083874A3 (en) 2005-12-22
WO2002083874A2 (en) 2002-10-24

Similar Documents

Publication Publication Date Title
CA2443995C (en) Endothelial cell expression patterns
CA2416732C (en) Endothelial cell expression patterns
KR100631766B1 (ko) 폴리펩티드, 그 폴리펩티드를 암호화하는 cDNA 및그들의 용도
KR20230160823A (ko) 치료 전달을 위한 조성물 및 방법
CN111848810A (zh) 一种蛋白质分子及其用途
KR20040095283A (ko) 종양에서 특이적으로 발현되는 유전자 산물 및 이의 용도
AU2002258543A1 (en) Endothelial cell expression patterns
JP5198354B2 (ja) メラノーマ関連ペプチド類似体およびメラノーマに対するワクチン
US20030143676A1 (en) Fibroblast growth factor receptors and methods for their use
JP2003000270A (ja) 腫瘍抗原
CN113185597B (zh) 一种可激活患者的抗肿瘤免疫反应的人肿瘤抗原及其应用
US20020102679A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU778585B2 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
JPWO2001062915A1 (ja) 新規蛋白質及びそれをコードする遺伝子
JPWO2002057444A1 (ja) ヒトアポトーシス関連遺伝子と、この遺伝子産物であるヒトアポトーシス関連蛋白質
HK1165476A (en) In tumours differentially expressed gene products and use of the same
WO2003074556A1 (fr) Marqueur tumoral et ses applications
HK1165484A (en) In tumours differentially expressed gene products and use of the same
JP2001224378A (ja) ヒト蛋白質とcDNA[7]
HK1165461A (en) In tumours differentially expressed gene products and use of the same
HK1165480A1 (zh) 肿瘤内差异表达的基因产物及其应用
JP2003520025A (ja) p193タンパク質、並びにその核酸及び使用
HK1165466A (en) In tumours differentially expressed gene products and use of the same
JPWO2003029466A1 (ja) 小型中性アミノ酸を輸送するナトリウム非依存性トランスポーター及びその遺伝子、及びその機能特定を可能にした融合タンパク質作製によるトランスポーターの機能解析法
JP2001161368A (ja) ヒト蛋白質とcDNA[3]

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20220411